Journal
DRUG DISCOVERY TODAY
Volume 23, Issue 11, Pages 1848-1872Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.07.008
Keywords
-
Categories
Ask authors/readers for more resources
Despite standardization of multimodal treatment and approval of several targeted drugs for resectable, non-metastatic cancer (MO patients), intrinsic and acquired resistance and relapse rates remain high, even in early-stage aggressive tumors. Genome analysis could overcome these unmet needs. Our comprehensive review underlines the controversy on stable or spatiotemporally evolving clones as well as promising yet inconclusive data on genome-based biomarkers and drug development. We propose clinicogenomic trials in M0 patients for the validation of intratumor heterogeneity (ITH), circulating genomic subclones (cGSs) and intra-patient genomic heterogeneity (IPGH) as biomarkers and simultaneous discovery of novel oncotargets. This evidence-based strategy highlights the coming of precision surgical oncology with a future perspective of understanding and disrupting deregulated transcriptional networks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available